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Late graft failure (LGF) without evidence of residual recipient cells is a serious complication 
after allogeneic hematopoietic stem cell transplantation (allo-SCT) and often requires stem 
cell infusion from the same donor when the patient fails to respond to conventional therapies. 
We screened the peripheral blood (PB) of 14 patients who developed donor-type LGF at 
2–132 months after allo-SCT for the presence of the markers for immune-mediated bone 
marrow (BM) failure. Increased glycosylphosphatidyl inositol-anchored protein-deficient 
(GPI-AP
-
) leukocytes, which accounted for 0.009–0.147% of the total granulocytes, were 
detected in five (severe aplastic anemia, n=2; follicular lymphoma, n=1; acute lymphoblastic 
leukemia, n=1; and myelodysplastic syndromes [MDS], n=1) and 4.7–81.2% HLA-allele 
lacking leukocytes (HLA-LLs) were detected in two (acute myeloid leukemia, n=1; and MDS, 
n=1) patients. Three of the five patients with increased GPI-AP
- 
leukocytes were treated with 
antithymocyte globulin (ATG) and two patients achieved transfusion independence. These 
results suggest that immune-mechanisms that are similar to acquired aplastic anemia underlie 
condition of approximately half of the patients with donor-type LGF and that in patients with 
increased GPI-AP
-
 cells, donor-derived hematopoiesis may be restored by ATG therapy alone 
without donor stem cell infusion. 
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Late graft failure (LGF) without evidence of residual recipient cells is a serious complication 
after allogeneic hematopoietic stem cell transplantation (allo-SCT). Various factors, such as 
infections and chronic graft-versus-host disease (GVHD), are involved in the development of 
such donor-type LGF
1,2
. It is therefore difficult to identify the exact cause and to restore the 
graft function without performing a second transplant. One exceptionally treatable condition 
is immune-mediated bone marrow (BM) failure that is similar to acquired aplastic anemia 
(AA). This condition occurs during donor-derived hematopoiesis, and can be diagnosed by 
identifying immune markers in the peripheral blood (PB). The markers include 





) and HLA allele-lacking leukocytes (HLA-LLs) due to copy number-neutral loss of 
heterozygosity in the short arm of chromosome 6 (6pLOH
5,6
) or missense mutations in the 
HLA alleles
7
, which can be found in 50% and 25% of patients with newly diagnosed AA, 
respectively. To determine how often such immune mechanisms are involved in the 
development of donor-type LGF, we retrospectively analyzed the laboratory data and clinical 







During the eight-year period from 2007 to 2015, 17 patients with LGF after allo-SCT were 
referred to our clinic to undergo a closer examination for LGF. All patients showed initial 
engraftment but subsequently developed loss of a previously functioning graft defined by at 
least two cytopenic lines 
8




/L before the 
development of LGF. Three of the 17 patients were diagnosed with LGF due to mixed 
chimerism, while the other 14 patients were diagnosed with donor-type LGF based on the 
absence of recipient-derived T cells, which was demonstrated by the amplification of short 
tandem repeat markers or a fluorescence in situ hybridization (FISH) analysis of the sex 
chromosomes. None of the 14 patients had apparent signs of GVHD, infections, or drug 
reactions at the time of LGF development. Eleven of the 14 patients were dependent on 
transfusions (eight on red blood cell and eight on platelet transfusions).The medical records 
(including the prevalence of increased GPI-AP
-
 cells and HLA-LLs) and treatment outcomes 
of the 14 patients with donor-type LGF were reviewed. The study protocol (No. 287) was 
approved by the Ethics Committee for Human Genome/Gene Analysis Research at Kanazawa 
University Graduate School of Medical Science. All of the patients provided their informed 
consent prior to participation in the study.  
The detection of GPI-AP
-
 cells and HLA-LLs 
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PB was collected from the patients at the time of the diagnosis and from the donor in Cases 1, 
3 and 6. To detect GPI-AP
-
 PNH-type cells, we performed high-sensitivity flow cytometry of 
the granulocytes and erythrocytes, as described previously
3
















 RBCs was defined as an abnormal increase based on the reference 
ranges in healthy individuals
9
. In our previous study, none of 51 SCT recipients without graft 




. For patients who did not show 
increased GPI-AP
-
 cells, we attempted to detect HLA-LLs. The expression of HLA-A on 
granulocytes, monocytes, B and T cells was analyzed by flow cytometry using a FACS Canto 
II (Becton Dickinson, Franklin Lakes, NJ, USA) with the FlowJo program (Tree Star, Ashland, 
OR, USA). This study used monoclonal antibodies specific for HLA-A24, A2, A26, and A31 
as well as the lineage marker antibodies specific for CD33 in granulocytes and monocytes, 
CD19 in B cells and CD3 in T cells, as described previously
5
. HLA-A allele lacking 
leukocytes were not detected in any of 8 SCT recipients who did not develop LGF. 
The SNP array analysis and the deep sequencing of the HLA-A gene 
PB was collected from the patient and the donor in Case 6. The DNA extracted from isolated 
granulocyte was subjected to genomic and allele-specific copy number analyses using 
GeneChip® 250K arrays (Affymetrix, Inc., Santa Clara, CA, USA), as previously 
described
10,11
. The genomic abnormalities responsible for the failure of HLA-A allelic 
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expression were also analyzed using Illumina MiSeq and HiSeq sequencing systems (Illumina, 
San Diego, CA, USA). 
The statistical analysis 
Overall survival (OS) was calculated as the number of months from the diagnosis of LGF 
until death or the last follow-up examination. The survival time was estimated by the 
Kaplan-Meier method and compared by a log-rank test. Two-sided P values were calculated, 
and P values of <0.05 were considered to indicate statistical significance. All of the statistical 
analyses were performed using the EZR software package (Saitama Medical Center, Jichi 
Medical University), a graphical user interface for the R software program (The R Foundation 








The prevalence of the immune markers in patients with LGF 
GPI-AP
-
 granulocytes ranging from 0.009–0.147% were detected in 5 of the 14 patients 
(35.7%, Figure 1). Five patients who did not show an increase in GPI-AP
-
 granulocytes and 
who were heterozygous for the HLA-A allele were subjected to FCM to detect HLA-LLs. 
4.7–81.2% HLA-LLs were detected in 2 of the 5 (40%) patients (Figure 2). All of the 14 
patients showed prominent thrombocytopenia at the onset of LGF, which gradually 
progressed to pancytopenia; their platelet counts were 7–40×109/L (median 18.5×109/L) and 
their neutrophil counts were 0.3–3.8×109/L (median 0.9×109/L).  
The clinical courses of the seven patients 
Table 1 summarizes the clinical characteristics of the seven patients who possessed immune 




 cells or 
FLAER
-
 cells in the granulocytes at the development of LGF. The numbers denote the 
proportion of GPI-AP
-
 cells in the CD11b
+
 granulocytes. 
 Case 1’s clinical course was previously reported4. Briefly, 0.147% GPI-AP- granulocytes 
(Figure 1) and 0.019% GPI-AP
- 
erythrocytes were detected in the PB of the patient after 2
nd
 
stem cell transplantation (SCT) for severe aplastic anemia (SAA) when the patient developed 
donor-type LGF. An increase in GPI-AP
-
 cells was not detected in the PB of the donor. We 
treated the patient with antithymocyte globulin (ATG) and cyclosporine. The patient achieved 
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a complete hematological recovery and has been in complete remission for 10 years after the 
ATG therapy. 
Case 2 had SAA. The patient was negative for increased GPI-AP
-
 cells and did not 
respond to ATG plus cyclosporine therapy. He underwent BM transplantation (BMT) from an 
unrelated donor whose HLA allele showed a 2-loci mismatch. Although his platelet count 
once increased to 96×10
9
/L on day 44 after BMT, it gradually decreased to 15×10
9
/L in 
parallel with the progression of anemia and leukocytopenia. A PB sample obtained at 7 
months after BMT showed 0.009% GPI-AP
-
 granulocytes (Figure 1). At 9 months after BMT, 
he was treated with rabbit ATG therapy (Thymoglobulin, 3.5 mg/kg × 5 days) and his 














/L). Although the patient was 
transfusion-independent for 6 weeks, his pancytopenia progressed again at 4 months after 
ATG therapy. The patient required red blood cell transfusions twice a month and platelet 
transfusions once a week as of 24 February 2017. A blood analysis at his most recent 
examination revealed the following findings: neutrophil count, 0.7×10
9
/L; hemoglobin, 6.7 
g/dL; platelet count, 18×10
9
/L and reticulocyte count, 25.5×10
9
/L.  
Case 3 received PB stem cell transplantation (PBSCT) from an HLA-haploidentical son 
for the treatment of follicular lymphoma that was refractory to chemotherapy. When the 
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patient developed donor-type LGF at 7 years after PBSCT, 0.125% GPI-AP
-
 granulocytes 
(Figure 1) were detected in the PB of the patient. The patient’s donor was negative for 
increased GPI-AP
-
 cells. She received rabbit ATG therapy (3.75 mg/kg × 5 days) and 
cyclosporine (6mg/kg/day) at 2 weeks after the development of pancytopenia, but the severe 
neutropenia persisted and she did not respond to G-CSF. At 6 weeks after ATG therapy, she 




 cells) from the original donor to promote 
hematological recovery. Her neutrophil count increased to 2.7×10
9
/L 68 days after the PBSC 
infusion without conditioning, but decreased to 0.1×10
9
/L again on day 134 after the infusion. 
She eventually received a conditioning regimen consisting of fludarabin (162 mg/m
2
), 
busulfan (6.4 mg/kg) and ATG (5 mg/kg) followed by a third PBSCT from the original donor 
at 6 months after ATG therapy. Her post-transplant course was uncomplicated and her 
complete blood cell counts were normal at 57 months after the third PBSCT. GPI-AP
-
 cells 
were undetectable when her blood was examined at one month after PBSCT.  
Case 4 was a 57-year-old woman who received HLA 2-loci-mismatched umbilical cord 
blood transplantation (CBT) for the treatment of acute lymphoblastic leukemia. When she 
developed donor-type LGF at 7 years after CBT, 0.011% GPI-AP
-
 granulocytes were detected 
in her PB (Figure 1). Because she declined ATG therapy, cyclosporine (6 mg/kg/day) was 
administered for 11 months without an appreciable response. In the four years since 




Case 5, a 25-year-old man, received a BMT from an HLA-matched unrelated donor for the 
treatment of MDS-refractory cytopenia of multilineage dysplasia (RCMD). His platelet count 
increased to 114×10
9
/L on day 44, but gradually decreased thereafter. When he was diagnosed 
with donor-type LGF on day 175 after the BMT, 0.016% GPI-AP
-
 granulocytes were detected 
in his PB (Figure 1). However, the patient chose to undergo a second BMT from an 
HLA-matched unrelated donor rather than IST, following conditioning with fludarabin (125 
mg/m²) and melphalan (140 mg/m²). The second BMT was successful and a sustained 
hematologic recovery was achieved. A laboratory analysis on October 26, 2016 revealed the 
following findings: neutrophil count, 2.7×10
9




Case 6 was a 23-year-old woman who underwent PBSCT from her HLA-haploidentical 
father for the treatment of acute myeloid leukemia with FLT3-internal tandem duplication. 
After neutrophil engraftment on day 19, she developed a generalized skin rash and high fever. 
After severe acute GVHD (grade II) was diagnosed, methylprednisolone (2 mg/kg/day) was 
started on day 24 and her skin rash quickly resolved. Platelet engraftment occurred on day 27 
and her platelet count reached 119×10
9
/L on day 38. However, her platelet count gradually 
decreased thereafter, and when her platelet count fell to 33.0×10
9
/L on day 89, her PB was 
negative for GPI-AP
-
 cells. Since the patient’s donor was heterozygous for the HLA-A allele 
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(A2 and A24), we examined her PB granulocytes for the presence of HLA-LLs—15% of the 
total granulocytes were negative for HLA-A2. HLA-A2-lacking leukocytes were not 
detectable in the PB of her donor (Figure 2A).  
Since her thrombocytopenia was mild, she was observed and the administration of tacrolimus 
and prednisolone—which had been prescribed for acute GVHD treatment—was continued. 
Her platelet counts showed a slight increase and stabilized at around 100×10
9
/L thereafter. 
The HLA-A2-lacking leukocytes gradually increased and accounted for 81.2% of the total 
granulocytes on day 167, but the percentage subsequently decreased and became undetectable 
on day 287 (Figure 2B). Her platelet count remained stable at 31 months after PBSCT. To 
identify the mechanisms responsible for the lack of the HLA-A allele, the patient’s 
granulocytes obtained on day 118 were subjected to a single nucleotide polymorphism (SNP) 
array analysis and granulocytes obtained on day 126 were used for the deep sequencing of the 
HLA-A gene. The donor’s granulocytes were used as a control. We did not detect a copy 
number-neutral 6pLOH or structural gene mutations of HLA-A*02:01 (Supplementary Figure 
1).  
Case 7 was a 63-year-old man who received a HLA-2-loci-mismatched CBT for the 
treatment of RCMD. Neutrophil and platelet engraftment were achieved on days 18 and 43 
after CBT, respectively, and his platelet count increased to 139×10
9
/L on day 134. When the 
patient developed donor-type LGF at 21 months after CBT, 4% of the total monocytes were 
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HLA-A26-lacking (Figure 2A). He was treated with cyclosporine (6 mg/kg) for one month 
without effect and died of systemic adenovirus infection at two months after the initiation of 
treatment.  
The clinical courses of the seven patients (Cases 8-14) without immune markers 
The PB of seven patients did not show an increase in either of GPI-AP
-
 cells or HLA-LLs.  
They developed LGF at 3 to 84 months after SCT. Four of them suffered from severe 
pancytopenia and required frequent transfusions. Cases 8-10 were treated with cyclosporine 
and responded; however, Case 10 developed pancytopenia 5 months after the discontinuation 
of cyclosporine. Since a low percentage of recipient-derived lymphocytes appeared at the time 
of relapse, the patient was treated with donor lymphocyte infusion (DLI) and a good 
hematopoietic function was restored. Case 11, who was heavily dependent on red blood cell 
transfusions, responded to a dose escalation of tacrolimus, which was given as prophylaxis 
against GVHD. Case 12 received DLI from the original donor because graft failure caused by 
residual recipient lymphocytes, which were not be detected by a FISH analysis of the patient’s 
sex chromosomes, could not be excluded, and the pancytopenia resolved. Case 13 did not 
respond to anabolic steroids and died of diffuse pulmonary hemorrhage. Case 14’s LGF, 
which was associated with acute GVHD, was improved by corticosteroids and iron chelation 
therapy (Table 2). 
The HLA alleles of the patients and the donor 
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Table 3 shows the HLA alleles of the patients and their donors. Four donors of the seven 
patients possessed one of the four HLA class I alleles (A*02:01 and A*02:06) that we 
previously identified as being associated with susceptibility to AA
5
. An HLA-A allele 
(A*02:01) that was lost in the donor-derived granulocytes in Case 6 was not shared by the 
recipient; however, there was no evidence of residual recipient T cells. Figure 3 shows the OS 





The present study identified seven patients with donor-type LGF who possessed GPI-AP
-
 
cells or HLA-LLs that are known to reflect the immune pathophysiology of BM failure. In 
keeping with the proposed significance of the immune markers, two of the three patients who 
were treated with ATG showed a sustained or transient improvement of their hematopoietic 
function. The prevalence of the immune markers among the patients with donor-type LGF 
was 50%. Even the patients who were negative for the immune markers may have had 
immune-mediated BM failure because a good hematopoietic function was restored in four of 
the seven patients who were treated with cyclosporine or tacrolimus. It is therefore suggested 
that immune-mediated BM failure, which is similar to AA, may underlie donor-type LGF.  
The mechanism responsible for the development of immune-mediated BM failure is not 
clear. Cases 1 and 2 originally had SAA, while Cases 5 and 7 had MDS-RCMD, which could 
have been diagnosed as non-severe AA. The BM microenvironment of these patients may 
predispose SCT recipients to developing immune mediated BM failure. However, this 
hypothesis does not explain the development of BM failure in the other three patients who 
had hematologic malignancies before SCT. Alternatively, the donors might have had genes 
that were associated with susceptibility to immune-mediated BM failure. We previously 
revealed that four class I HLA alleles (A*02:01, A*02:06, A*31:01 and B*40:02) are 
associated with susceptibility to AA. HLA-DRB1*15:01 and 15:02 have also been shown to 
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be associated with immune-mediated BM failure
11
. With the exception of Case 7, all of the 
subjects in the present study possessed one of these high-risk HLA-alleles. Of note, Case 6 
did not possess any of the high-risk class I alleles but the patient’s donor possessed 
HLA-A*02:01, which was missing in 15% of the total granulocytes when the patient 
developed thrombocytopenia. In these patients with donor-type LGF, certain triggers (such as 
infections or drugs) might have induced the breakdown of immune tolerance to hematopoietic 
stem cells, leading to the development of BM failure. 
Both an SNP array analysis and the deep sequencing of the HLA-A gene failed to detect 
mutations in the HLA-A*02:01 that would have accounted for the lack of HLA-A2 in the 
Case 6’s granulocytes. Our recent analyses of the HLA-B*40:02 gene in AA patients 
possessing HLA-B*40:02-lacking granulocytes revealed various mutations in the aberrant 
granulocytes of all patients
13
. However, we previously experienced some patients whose 
granulocytes, which lacked HLA-A*31:01, did not show any mutations involving this A allele 
and did not express its mRNA (unpublished observation). Thus, epigenetic mechanisms may 
have been involved in the transient appearance of HLA-A2-lacking granulocytes in Case 6. 
LGF has been defined as hematopoietic failure secondary to neutrophil engraftment. Some 
patients who meet this criterion do not achieve platelet engraftment and require regular 
platelet transfusions. We excluded patients with persistent thrombocytopenia from the present 
study because their hematopoietic failure is primarily caused by the poor engraftment of 
17 
 
donor HSCs due to the infusion of an insufficient number of HSCs. In reality, none of eight 
patients with persistent thrombocytopenia showed an increase in GPI-AP
-
 cells or HLA-LLs 
(unpublished observation). Similar to acquired AA, thrombocytopenia was the first sign of 
LGF in the seven patients with increased numbers of GPI-AP
-
 cells or HLA-LLs. It is 
therefore important to bear in mind that progressive thrombocytopenia precedes 
immune-mediated hematopoietic failure in donor hematopoiesis. 
In conclusion, immune-mediated BM failure similar to AA is a common in patients with 
donor-type LGF after allo-SCT; GPI-AP
-
 cells or HLA-LLs were detected in half of the 
patients. This immune-mediated BM failure may be potentially curable by ATG, without the 
need for a second SCT. When donor-type LGF occurs without preceding infections, GVHD or 
exposure to drugs, the patient’s blood should be screened for the presence of GPI-AP- cells 






The authors thank the patients and donors and their physicians. We also thank Ms Rie Oumi 
for her excellent technical assistance. We also thank the following physicians for providing 
patient data: K. Ohata of Kanazawa University, A. Seto and T. Sato of Japanese Red Cross 
Nagoya Daiichi Hospital, A. Yoshida of Toyama Prefectural Central Hospital, K. Yoshinaga of 
Tokyo Women’s Medical University Hospital, T. Takakuwa of Osaka City University Hospital, 
F. Monma of Mie University Hospital, M. Fujiwara of Tohoku University Hospital, K. Okada 
and T. Matsukawa of Hokkaido University Hospital and M. Yabe of Tokai University 
Hospital.  
 
Financial disclosure: The authors have nothing to disclose. 
Conflict of interest disclosure: The authors declare no conflicts of interest in association with 
the present study. 
Authorship contributions: S.N. initiated and designed the study; K.M. and S.N. wrote the 
manuscript. K.M., H.M., T.K., Y.Z., N.N., K.H. and S.O. performed the experiments and 






1. Dominietto A, Raiola AM, van Lint MT, et al. Factors influencing haematological 
recovery after allogeneic haemopoietic stem cell transplants: graft-versus-host disease, donor 
type, cytomegalovirus infections and cell dose. Br J Haematol 2001;112:219-27. 
2. Kong Y, Chang YJ, Wang YZ, et al. Association of an impaired bone marrow 
microenvironment with secondary poor graft function after allogeneic hematopoietic stem cell 
transplantation. Biol Blood Marrow Transplant 2013;19:1465-73. 
3. Sugimori C, Chuhjo T, Feng X, et al. Minor population of CD55-CD59- blood cells 
predicts response to immunosuppressive therapy and prognosis in patients with aplastic 
anemia. Blood 2006;107:1308-14. 
4. Mochizuki K, Sugimori C, Qi Z, et al. Expansion of donor-derived hematopoietic 
stem cells with PIGA mutation associated with late graft failure after allogeneic stem cell 
transplantation. Blood 2008;112:2160-2. 
5. Katagiri T, Sato-Otsubo A, Kashiwase K, et al. Frequent loss of HLA alleles 
associated with copy number-neutral 6pLOH in acquired aplastic anemia. Blood 
2011;118:6601-9. 
6. Maruyama H, Katagiri T, Kashiwase K, et al. Clinical significance and origin of 
leukocytes that lack HLA-A allele expression in patients with acquired aplastic anemia. 
Experimental hematology 2016;44:931-9.e3. 
7. Osumi T, Miharu M, Saji H, et al. Nonsense mutation in HLA-B*40:02 in a case with 
acquired aplastic anaemia: a possible origin of clonal escape from autoimmune insult. Br J 
Haematol 2013;162:706-7. 
8. Appelbaum FR, Thomas ED. Thomas' hematopoietic cell transplantation : stem cell 
transplantation. 4th ed. Oxford ; Hoboken, NJ: Wiley-Blackwell; 2008. 
9. Sugimori C, Yamazaki H, Feng X, et al. Roles of DRB1 *1501 and DRB1 *1502 in 
the pathogenesis of aplastic anemia. Experimental hematology 2007;35:13-20. 
10. Nannya Y, Sanada M, Nakazaki K, et al. A robust algorithm for copy number 
detection using high-density oligonucleotide single nucleotide polymorphism genotyping 
arrays. Cancer research 2005;65:6071-9. 
11. Yamamoto G, Nannya Y, Kato M, et al. Highly sensitive method for genomewide 
detection of allelic composition in nonpaired, primary tumor specimens by use of affymetrix 
single-nucleotide-polymorphism genotyping microarrays. American journal of human 
genetics 2007;81:114-26. 
12. Kanda Y. Investigation of the freely available easy-to-use software 'EZR' for medical 
statistics. Bone marrow transplantation 2013;48:452-8. 
13. Zaimoku Y, Takamatsu H, Hosomichi K, et al. Identification of an HLA class I allele 














Table 3. The HLA alleles of the donors and recipients of the seven patients who had 







Figure 1. The Analysis of the GPI-AP
-
 cells at the development of LGF. 
 
Figure 2. The analysis of HLA-LLs at the development of LGF and the clinical course of 
Case 6. 
(A) HLA-allele lacking leukocytes (HLA-LLs) were detected by flow cytometry. The 
numbers denote the proportion of HLA-LLs in the specific leukocyte compartment. In Case 6, 
HLA-A2-lacking leukocytes were detected in the granulocytes at the development of LGF, 
but none of them were detected in the donor. In Case 7, HLA-A26-lacking leukocytes were 
detected in the monocytes at the development of LGF. 
(B) In Case 6, acute GVHD developed on day 24 and thrombocytopenia developed on day 45 
after SCT. The proportion of HLA-A2-lacking leukocytes in granulocytes was followed. The 
percentage became undetectable on day 287.  
 
Figure 3. The OS of the 14 patients who were diagnosed with donor-type LGF according 
to the status of their GPI-AP
-














Supplementary Figure 1. SNP array analysis of chromosome 6 and deep sequencing of 
the HLA-A*02:01 gene 
 
 
(A) A copy number-neutral 6pLOH was not detected in the recipient’s granulocytes.  
(B) Alignment view of HLA-A*02:01 allelic sequences from the recipient’s granulocytes 
(Recipient) and the donor’s granulocytes (Donor). The allelic sequences were phased by 
phase-defined HLA gene sequencing pipeline
1
. In HLA-A gene region, allelic sequences of 
phased HLA-A*02:01 sequence of recipient and donor were completely identical and rare 
somatic mutations were not observed either. 
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